Chronic Cough Evaluation: A Systematic Diagnostic Approach
Sam Anderson
Initial Assessment and Red Flags
Chronic cough — defined as a cough lasting eight weeks or longer — accounts for a substantial proportion of outpatient visits to primary care and pulmonology. The differential diagnosis is broad, but a systematic approach that methodically evaluates the most common etiologies before pursuing invasive testing prevents unnecessary workups and identifies the cause in the vast majority of patients. For the primary care physician, pulmonologist, or allergist managing chronic cough, this review covers the stepwise diagnostic approach with emphasis on distinguishing the common treatable causes from the rare serious ones.
The ACCP 2024 updated guidelines recommend a systematic diagnostic protocol beginning with history, chest radiography, and ACE inhibitor discontinuation (cough resolves in 1-4 weeks after stopping in 50-80% of ACEi-associated cases[2]). Red flags requiring expedited workup include hemoptysis, weight loss, fever, immunosuppression, progressive dyspnea, abnormal chest radiograph (consider lung cancer screening criteria), and history of smoking with new or changed cough pattern. In nonsmokers with a normal chest radiograph who are not on ACE inhibitors (a common cause of cough also encountered in hypertension management), the three most common causes account for over 90% of cases: upper airway cough syndrome (UACS/postnasal drip, 34%), asthma/cough-variant asthma (25%), and gastroesophageal reflux (20%)[2].
Upper Airway Cough Syndrome
UACS presents with nasal congestion, throat clearing, and sensation of postnasal drainage, though silent UACS without these symptoms occurs in 20% of cases. First-generation antihistamine-decongestant combinations (e.g., chlorpheniramine-pseudoephedrine or dexbrompheniramine-pseudoephedrine) are more effective than second-generation antihistamines due to anticholinergic properties (NNT 4-5 for cough resolution at 2 weeks). Intranasal corticosteroids (fluticasone 200 mcg daily or mometasone 200 mcg daily) are first-line for allergic rhinitis-driven cough, with a meta-analysis showing 36% reduction in cough scores. Empiric treatment trial of 2-4 weeks is both diagnostic and therapeutic.
Cough-Variant Asthma and Eosinophilic Bronchitis
Cough-variant asthma (see also COPD guidelines for differential diagnosis) presents with isolated cough (no wheeze or dyspnea) and is confirmed by positive methacholine challenge (PC20 below 8 mg/mL) or reversible airflow obstruction on spirometry (FEV1 improvement of 12% and 200 mL post-bronchodilator). Inhaled corticosteroids (budesonide 200-400 mcg twice daily or fluticasone 125-250 mcg twice daily) are the treatment of choice, with cough resolution expected within 6-8 weeks. Non-asthmatic eosinophilic bronchitis (NAEB) accounts for 10-15% of chronic cough cases and is distinguished from asthma by normal methacholine challenge but elevated induced sputum eosinophils (above 3%)[1]. NAEB responds to inhaled corticosteroids with comparable efficacy.
Reflux-Associated Cough
GERD-related cough may occur without typical heartburn or regurgitation in up to 75% of cases (silent reflux). Empiric PPI therapy (omeprazole 40 mg daily or equivalent) for 8-12 weeks is the standard diagnostic-therapeutic approach. However, the COUGH-1 and COUGH-2 trials showed only modest benefit of PPIs over placebo for chronic cough, with NNT of 10-12. Ambulatory pH monitoring (24-hour catheter-based or wireless Bravo capsule) with symptom association probability (SAP above 95%) or symptom index (SI above 50%) provides objective evidence of reflux-cough association. Impedance-pH testing detects both acid and non-acid reflux events, increasing diagnostic sensitivity to 90%.
Refractory and Unexplained Chronic Cough
Approximately 5-15% of chronic cough cases remain unexplained despite comprehensive evaluation. Cough hypersensitivity syndrome, characterized by enhanced cough reflex sensitivity to environmental and chemical triggers, is increasingly recognized as the unifying mechanism. Gabapentin (300-1800 mg daily) reduced cough-specific quality of life by 33% compared to placebo in the randomized trial by Ryan et al. (NNT 3.6)[1]. Speech pathology-based cough suppression therapy achieves 50-60% improvement in cough frequency[1]. The P2X3 receptor antagonist gefapixant (45 mg twice daily) was FDA-approved in 2025 for refractory chronic cough, reducing cough frequency by 18.5% versus placebo (COUGH-1 trial), though taste disturbance (dysgeusia) occurs in 58% of patients at therapeutic doses[2].
The Overlap Problem and When to Treat Multiple Causes Simultaneously
The sequential empiric approach — treat UACS, then asthma, then reflux — is tidy in textbooks but messy in practice, because many patients have more than one contributing cause. A patient with allergic rhinitis driving UACS, mild bronchial hyperreactivity producing cough-variant asthma features, and subclinical reflux may not resolve until all three are addressed concurrently. When the sequential approach stalls after two adequate empiric trials, the clinician should consider parallel treatment of the remaining untested etiologies rather than continuing to add and subtract one therapy at a time. The PPI trial deserves particular scrutiny — the COUGH-1 and COUGH-2 data showing only modest PPI benefit with an NNT of 10-12 mean that many "reflux-associated" coughs may actually be non-acid reflux or laryngopharyngeal irritation that does not respond to acid suppression alone. Impedance-pH testing, while more invasive, provides the diagnostic clarity that an empiric PPI trial often cannot.
Limitations and the Honest Conversation About Refractory Cough
For the patient whose cough persists despite systematic evaluation and treatment of the common etiologies, the clinician faces the challenge of communicating uncertainty constructively. The gabapentin data (NNT 3.6) and speech pathology-based cough suppression results (50-60% improvement) offer genuine therapeutic options for refractory cases, but they also represent a shift in framing — from "we are looking for the cause" to "we are managing a heightened cough reflex that may not have a single identifiable trigger." Gefapixant's approval adds another option, but its 58% dysgeusia rate at therapeutic doses means that many patients will not tolerate it long-term. Acknowledging to the patient that the diagnostic algorithm has been thoroughly pursued and that management is now directed at cough sensitivity itself — rather than ordering additional tests with diminishing yield — is more helpful than perpetuating the expectation that the next scan or scope will provide the answer.
References
- An investigation into the effect of gabapentin on chronic cough: a randomised, double-blind, placebo-controlled trial PubMed 22951084
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials PubMed 35248186
Frequently Asked Questions
What are the three most common causes of chronic cough in nonsmokers?
How long does ACE inhibitor cough take to resolve after discontinuation?
What confirms cough-variant asthma diagnosis?
What is the NNT for gabapentin in refractory chronic cough?
Is gefapixant effective for refractory chronic cough?
How effective are PPIs for GERD-related chronic cough?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine